ICER has released a draft report that indicates Roctavian, BioMarin’s new gene therapy for hemophilia A, will beat the current antibody-based therapeutic Hemlibri. Unlike Hemlibri, which is a prophylactic, Roctavian restores the gene lacking in hemophilia A, factor VIII. The organization predicts […]
ICER Review Casts Doubt on Value of Two ALS Drug Candidates
A new report by the Institute for Clinical and Economic Review (ICER) finds that 2 amytrophic lateral sclerosis (ALS) drug candidates from Amylyx and Mitsubishi Tanabe Pharma America have “low long-term value at their current suggested prices. Although the drugs both provide some benefits over the […]
ICER Report At a Glance: Beti-Cel for Beta Thalassemia
Beta Thalassemia is a blood disorder that results in dangerously low levels of functional hemoglobin and requires expensive lifelong medical care, including regular blood transfusions. Beti-cel is a gene therapy by Bluebird Bio that can potentially cure the disorder by genetically modifying a […]
ICER Announces Initiative to Develop Health Equity-Targeted HTA Practices
Health technology assessment (HTA) agencies are primarily focused on efficacy and safety of a therapeutic on a general population. A new initiative by the Institute for Clinical and Economic Review (ICER) seeks to add another criteria to the mix: health equity. The non-profit recently received […]
ICER Signals Concern About Price for Amylyx’s ALS Drug
The Institute for Clinical and Economic Review (ICER) has released a draft report detailing their concerns surrounding Amylyx Pharmaceutical’s new ALS drug Albrioza/AMX0035. The drug has just been conditionally approved in Canada and will likely receive a decision from the US Food and Drug […]
ICER Will Assess Value and Effectiveness of Multiple Sclerosis Treatments
The Institute for Clinical and Economic Review (ICER) will perform value and effectiveness assessments on several drugs for multiple sclerosis. The drugs include several monoclonal antibody treatments from manufacturers like Biogen, Novartis, and Genentech and some biosimilars for Rituximab. The […]
ICER White Paper – Rare Disease Drug Policy Reform, Drug Access, and Innovation
Despite the advancements in rare disease treatment, patients with many rare diseases still have extremely limited, if any, treatment options. Changes in regulatory approval for rare disease drugs like the Orphan Drug Act have helped to bring new treatments to the clinic, but some worry whether the […]
ICER Will Develop California State Unsupported Price Reports
The California Health Care Foundation (CHCF) has awarded The Institute for Clinical and Economic Review (ICER) a new grant to develop 2 California-specific unsupported price increase reports. In addition, the grant will support the development of a policymaker guide to use comparative effectiveness […]
ICER: Final Evidence Report and Policy Recommendations on Tirzepatide Now Available
The Institute for Clinical and Economic Review (ICER) just released their final evidence report on the diabetes 2 drug terzepatide. ICER found adequate evidence that Eli Lilly’s drug improved symptoms but did not find it had benefits over injectable semaglutide. The institute also determined that […]
ICER Releases Draft Report on Plinabulin and Trilaciclib for Chemo-induced Neutropenia
The Institute for Clinical and Economic Review (ICER) has released its draft evidence report for the novel drugs plinabulin (BeyondSpring Pharmaceuticals) and trilaciclib (Cosela™, G1 Therapeutics). The report assessed the comparative clinical effectiveness and value of the two drugs that are […]
